Poster-Disease-modifying Therapy
October 25, 2021
Assessment of Composite Disability Accumulation of Ponesimod Relative to Teriflunomide in the Optimum Phase 3 Study
Background: In relapsing forms of Multiple Sclerosis, disability progression has been shown to be independent of relapses. A new concept in...
Poster-Disease-modifying Therapy
October 25, 2021
MS Fatigue: Treatment Effect of Ponesimod in RMS Patients with and without Disease Activity
Background: NEDA or No evidence of disease activity (relapses, MRI lesions and disease progression) is increasingly used as a meaningful...